Cargando…

Recent Advances in NAMPT Inhibitors: A Novel Immunotherapic Strategy

Nicotinamide adenine dinucleotide (NAD) is a cofactor of many enzymatic reactions as well as being a substrate for a number of NAD-consuming enzymes (e.g., PARPS, sirtuins, etc). NAD can be synthesized de novo starting from tryptophan, nicotinamide, nicotinic acid, or nicotinamide riboside from the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Galli, Ubaldina, Colombo, Giorgia, Travelli, Cristina, Tron, Gian Cesare, Genazzani, Armando A., Grolla, Ambra A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235340/ https://www.ncbi.nlm.nih.gov/pubmed/32477131 http://dx.doi.org/10.3389/fphar.2020.00656

Ejemplares similares

Data on metabolic stability, aqueous solubility and CYP inhibition of novel triazole-based nicotinamide phosphoribosyltransferase (NAMPT) inhibitors
por: Aprile, Silvio, et al.
Publicado: (2019)

The Cytokine Nicotinamide Phosphoribosyltransferase (eNAMPT; PBEF; Visfatin) Acts as a Natural Antagonist of C-C Chemokine Receptor Type 5 (CCR5)
por: Torretta, Simone, et al.
Publicado: (2020)

The NAMPT inhibitor FK866 reverts the damage in spinal cord injury
por: Esposito, Emanuela, et al.
Publicado: (2012)

Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) neutralization counteracts T cell immune evasion in breast cancer
por: Travelli, Cristina, et al.
Publicado: (2023)

NAMPT and NAPRT serum levels predict response to anti-TNF therapy in inflammatory bowel disease
por: Colombo, Giorgia, et al.
Publicado: (2023)

Extracellular nicotinamide phosphoribosyltransferase, a new cancer metabokine
por: Grolla, Ambra A, et al.
Publicado: (2016)

Insight Into Nicotinamide Adenine Dinucleotide Homeostasis as a Targetable Metabolic Pathway in Colorectal Cancer
por: Colombo, Giorgia, et al.
Publicado: (2021)

Extracellular nicotinamide phosphoribosyltransferase boosts IFNγ-induced macrophage polarization independently of TLR4
por: Colombo, Giorgia, et al.
Publicado: (2022)

Review of various NAMPT inhibitors for the treatment of cancer
por: Wei, Yichen, et al.
Publicado: (2022)

The Guareschi Pyridine Scaffold as a Valuable Platform for the Identification of Selective PI3K Inhibitors
por: Galli, Ubaldina, et al.
Publicado: (2015)

Visfatin/PBEF/Nampt: A New Cardiovascular Target?
por: Peiró, Concepción, et al.
Publicado: (2010)

Exploiting the Nucleophilicity of the Nitrogen Atom of Imidazoles: One-Pot Three-Component Synthesis of Imidazo-Pyrazines
por: Galli, Ubaldina, et al.
Publicado: (2019)

What’s in a Name? Drug Nomenclature and Medicinal Chemistry Trends using INN Publications
por: Serafini, Marta, et al.
Publicado: (2021)

From Rate-Limiting Enzyme to Therapeutic Target: The Promise of NAMPT in Neurodegenerative Diseases
por: Zhu, Yumeng, et al.
Publicado: (2022)

New strategies to maximize therapeutic opportunities for NAMPT inhibitors in oncology
por: Roulston, Anne, et al.
Publicado: (2015)

Editorial: Liquid Biopsy as a Tool for Precision Oncology: New Challenges to Assess Clinical Response
por: Ravegnini, Gloria, et al.
Publicado: (2020)

Linkage of NAMPT promoter variants to eNAMPT secretion, plasma eNAMPT levels, and ARDS severity
por: Lynn, Heather, et al.
Publicado: (2023)

Recent Advances in the Synthesis of Polyamine Derivatives and Their Applications
por: Nichugovskiy, Artemiy, et al.
Publicado: (2021)

Targeting NAMPT as a therapeutic strategy against stroke
por: Wang, Shu-Na, et al.
Publicado: (2019)

Structural Basis for Resistance to Diverse Classes of NAMPT Inhibitors
por: Wang, Weiru, et al.
Publicado: (2014)

Discovery of Novel Inhibitors and Fluorescent Probe Targeting NAMPT
por: Wang, Xia, et al.
Publicado: (2015)

Drug repositioning strategy for the identification of novel telomere‐damaging agents: A role for NAMPT inhibitors
por: Rizzo, Angela, et al.
Publicado: (2023)

HGG-33. EXPLOITING METABOLIC DEFECTS WITH NAMPT INHIBITORS IN DIPG
por: Muraleedharan, Ranjithmenon, et al.
Publicado: (2021)

Recent Advances in Nano-Therapeutic Strategies for Osteoarthritis
por: Guo, Xinjing, et al.
Publicado: (2022)

Recent progress in DNA methyltransferase inhibitors as anticancer agents
por: Zhang, Zhixiong, et al.
Publicado: (2022)

Recent advances in JAK inhibitors for the treatment of metabolic syndrome
por: Collotta, Debora, et al.
Publicado: (2023)

eNAMPT/TLR4 inflammatory cascade activation is a key contributor to SLE Lung vasculitis and alveolar hemorrhage
por: Tumurkhuu, Gantsetseg, et al.
Publicado: (2022)

Prostaglandin E2 and Cancer: Insight into Tumor Progression and Immunity
por: Finetti, Federica, et al.
Publicado: (2020)

The NAMPT Inhibitor FK866 in Combination with Cisplatin Reduces Cholangiocarcinoma Cells Growth
por: Pant, Kishor, et al.
Publicado: (2023)

OXER1 and RACK1-associated pathway: a promising drug target for breast cancer progression
por: Masi, Mirco, et al.
Publicado: (2020)

Nanosystems for chemodynamic based combination therapy: Strategies and recent advances
por: Li, Minghui, et al.
Publicado: (2022)

Recent advances of IDH1 mutant inhibitor in cancer therapy
por: Tian, Wangqi, et al.
Publicado: (2022)

Synthesis and Characterization of Bis-Triazolyl-Pyridine Derivatives as Noncanonical DNA-Interacting Compounds
por: Di Porzio, Anna, et al.
Publicado: (2021)

Endothelial eNAMPT drives EndMT and preclinical PH: rescue by an eNAMPT-neutralizing mAb
por: Ahmed, Mohamed, et al.
Publicado: (2021)

Recent advances in peptide-based therapeutic strategies for breast cancer treatment
por: Li, Ling, et al.
Publicado: (2023)

A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT
por: Barraud, Marine, et al.
Publicado: (2016)

Preclinical efficacy of the novel competitive NAMPT inhibitor STF-118804 in pancreatic cancer
por: Espindola-Netto, Jair Machado, et al.
Publicado: (2017)

NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in Melanoma
por: Audrito, Valentina, et al.
Publicado: (2020)

The NAMPT Inhibitor FK866 Increases Metformin Sensitivity in Pancreatic Cancer Cells
por: Parisotto, Maxime, et al.
Publicado: (2022)

13th International Meeting on Reduced Enrichment for Research and Test Reactors
por: Travelli, Armando
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_5g2keaqrja6s269scnt1g6fi5d